Maintenance Tislelizumab Combined With Capecitabine to Treat Metastatic Colorectal Cancer With No Evidence of Disease
Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.
• Age ≥ 20 years, \< 80 years
• Written informed consent
• Histologically or cytologically confirmed CRC
• Surgery with integrated treatment for metastatic colorectal cancer (mCRC) and achieved a statute of no evidence of disease (NED), as determined by a multidisciplinary tumor board.
• cytoreduction surgery achieves CC0 (no visible residual tumor) if there is peritoneal metastasis
• No previous chemotherapy
• Synchronous or metachronous metastatic disease: maximum of two distant organs or regions involved
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Adequate hematologic and organ function